Personalized diagnosis using bioinformatics

Genetesis specializes in advanced cardiac imaging technology through its innovative CardioFlux system, which utilizes magnetocardiography (MCG) to detect functionally significant ischemia at its earliest stages. This non-invasive approach allows for rapid diagnosis, with scans completed in as little as five minutes, significantly reducing the time patients spend in emergency settings. The CardioFlux system measures the magnetic fields generated by the heart's electrical activity, providing a reliable and efficient alternative to traditional diagnostic methods such as ECGs and stress tests. This technology aims to enhance patient care by enabling earlier detection of myocardial ischemia, thereby improving treatment outcomes and reducing hospital stays.

The company emphasizes the integration of 40 years of proven scientific research into clinical workflows, ensuring that CardioFlux is not only effective but also scalable for widespread use in emergency medicine. Genetesis is actively involved in clinical trials to validate the efficacy of MCG in diagnosing conditions like coronary microvascular dysfunction (CMD) and to establish its role in the standard of care for ischemic heart disease. By partnering with various healthcare institutions, Genetesis is committed to evolving cardiac diagnostics and addressing pressing healthcare challenges through its innovative technology.

United States

Genetesis is a rapidly growing medical imaging company leveraging data science and biomagnetism in the fight against cardiovascular disease.

Genetesis

Company Details